No studies have been retrieved comparing perfluorobutane with sulfur hexafluoride for microwave ablation (MWA) in small hepatocellular carcinoma(sHCC).
OBJECTIVE:
To retrospective investigate the value of perfluorobutane ultrasonography contrast agent in ultrasonography (US)-guided MWA of sHCC.
METHODS:
We conducted a retrospective clinical controlled study about US-guided percutaneous MWA in patients with sHCC, and in patients undergoing intra-operative treatment with perfluorobutane or sulfur hexafluoride. In both groups, a contrast agent was injected to clear the tumor and then a needle was inserted. A 5-point needle prick difficulty score was developed to compare needle prick difficulty in the two groups of cases.
RESULTS:
A total of 67 patients were included: 25 patients in group perfluorobutane, aged 41–82 (60.64±9.46), tumor size 1.1–2.8 (1.78±0.45) cm. 42 patients in group sulfur hexafluoride, aged 38–78 (62.26±9.27), with tumor size of 1.1–3.0 (1.89±0.49) cm. There was no significant difference in age or tumor size in both groups (P > 0.05). Puncture difficulty score (5-point): 2.0–2.7 (2.28±0.29) in group perfluorobutane, and 2.0–4.7 (2.95±0.85) in group sulfur hexafluoride, and the difference between the two groups was statistically significant (P < 0.05). Enhanced imaging results within 3 months after surgery: complete ablation rate was 100% (25/25) in the group perfluorobutane, 95.2% (40/42 in the group sulfur hexafluoride), with no significant difference between the two groups (P > 0.05).
CONCLUSION:
Perfluorobutane kupffer phase can make the operator accurately deploy the ablation needle and reduce the difficulty of operation.
AhnKS, KangKJ. Appropriate treatment modality for solitary small hepatocellular carcinoma: Radiofrequency ablation vs resection vs. transplantation? Clinical and Molecular Hepatology2019;25(4):354–9.
2.
AnC, LiW, HuangZ, YuX, HanY, LiuF, et al. Small single perivascular hepatocellular carcinoma: comparisons of radiofrequency ablation and microwave ablation by using propensity score analysis. Eur Radiol2021;31(7):4764–73.
3.
YeC, ZhangW, PangZ, WangW. Efficacy of liver cancer microwave ablation through ultrasonic image guidance under deep migration feature algorithm. Pak J Med Sci2021;37(6):1693–8.
4.
DietrichCF, NolsøeCP, BarrRG, BerzigottiA, BurnsPN, CantisaniV, et al. Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound Med Biol2020;46(10):2579–604.
5.
WangP, NieF, DongT, WangG, WangL, FanX. Study on correlation between two-dimensional ultrasound, contrast-enhanced ultrasound and microvascular invasion in hepatocellular carcinoma. Clin Hemorheol Microcirc2022;80(2):97–106.
6.
Meitner-SchellhaasB, JesperD, GoertzRS, ZundlerS, StrobelD. Washout appearance of hepatocellular carcinomas using standardized contrast-enhanced ultrasound (CEUS) including an extended late phase observation –Real-world data from the prospective multicentre DEGUM study. Clin Hemorheol Microcirc2023;84(4):413–24.
7.
BarrRG, HuangP, LuoY, XieX, ZhengR, YanK, et al. Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid. Abdom Radiol2020;45(11):3779–88.
8.
KangHJ, LeeJM, YoonJH, YooJ, ChoiY, JooI, et al. Sonazoidtrademark versus SonoVue(®) for diagnosing hepatocellular carcinoma using contrast-enhanced ultrasound in at-risk individuals: a prospective, single-center, intraindividual, noninferiority study. Korean J Radiol2022;23(11):1067–77.
9.
ZhengZ, XieW, TianJ, WuJ, LuoB, XuX. Utility of sonazoid-enhanced ultrasound for the macroscopic classification of hepatocellular carcinoma: a meta-analysis. Ultrasound Med Biol2022;48(11):2165–73.
10.
MukundA, BansalA, PatidarY, ThaparS, SharmaMK, SarinSK. Role of contrast-enhanced ultrasound with Perfluorobutane in lesion detection, guidance for microwave ablation, and response assessment of hepatocellular carcinoma. Abdom Radiol2022;47(10):3459–67.
11.
ParkJH, ParkMS, LeeSJ, JeongWK, LeeJY, ParkMJ, et al. Contrast-enhanced US with perfluorobutane for hepatocellular carcinoma surveillance: A multicenter diagnostic trial (SCAN). Radiology.2019;292(3):638–46.
12.
DongY, ZuoD, QiuYJ, CaoJY, WangHZ, YuLY, et al. Preoperative prediction of microvascular invasion (MVI) in hepatocellular carcinoma based on kupffer phase radiomics features of sonazoid contrast-enhanced ultrasound (SCEUS): A prospective study. Clin Hemorheol Microcirc2022;81(1):97–107.
13.
ZhangW, LiuY, WuQ, WeiX, LiuB, JiaoQ, et al. Pitfalls and strategies of Sonazoid enhanced ultrasonography in differentiating metastatic and benign hepatic lesions. Clin Hemorheol Microcirc. 2023.
14.
TamaiH, OkamuraJ. New next-generation microwave thermosphere ablation for small hepatocellular carcinoma. Clinical and Molecular Hepatology2021;27(4):564–74.
15.
MinamiY, KudoM. Image guidance in ablation for hepatocellular carcinoma: Contrast-enhanced ultrasound and fusion imaging. Front Oncol2021;11:593636.
16.
ZhaiHY, LiangP, YuJ, CaoF, KuangM, LiuFY, et al. Comparison of Sonazoid and SonoVue in the diagnosis of focal liver lesions: a preliminary study. J Ultrasound Med2019;38(9):2417–25.
17.
ZhongX, PengJ, XieY, ShiY, LongH, SuL, et al. A nomogram based on multi-modal ultrasound for prediction of microvascular invasion and recurrence of hepatocellular carcinoma. Eur J Radiol2022;151:110281.
18.
XianMF, LiW, LanWT, ZengD, XieWX, LuMD, et al. Strategy for accurate diagnosis by contrast-enhanced ultrasound of focal liver lesions in patients not at high risk for hepatocellular carcinoma: A preliminary study. J Ultrasound Med2022;42(6):1333–44.
19.
LiW, LvXZ, ZhengX, RuanSM, HuHT, ChenLD, et al. Machine learning-based ultrasomics improves the diagnostic performance in differentiating focal nodular hyperplasia and atypical hepatocellular carcinoma. Front Oncol11 (2021)544979.
20.
WangW, WuSS, ZhangJC, XianMF, HuangH, LiW, et al. Preoperative pathological grading of hepatocellular carcinoma using ultrasomics of contrast-enhanced ultrasound. Acad Radiol2021;28(8):1094–101.
21.
LiCQ, ZhengX, GuoHL, ChengMQ, HuangY, XieXY, et al. Differentiation between combined hepatocellular carcinoma and hepatocellular carcinoma: comparison of diagnostic performance between ultrasomics-based model and CEUS LI-RADS v2017. BMC Med Imaging. 2022;22(1):36.
22.
GuoHL, ZhengX, ChengMQ, ZengD, HuangH, XieXY, et al. Contrast-enhanced ultrasound for differentiation between poorly differentiated hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Ultrasound Med2022;41(5):1213–25.
23.
LuoL, YanR, ZengQ, LongY, HeX, LiK, et al. Radiofrequency ablation of hepatocellular carcinomas adjacent to the gallbladder without isolation under contrast-enhanced ultrasound monitoring: A comparative study with long term follow-uJ Hepatocell Carcinoma10 (2023)631–42.
24.
XiaoL, ZhouJ, TanW, LiuY, ZhengH, WangG, et al. Contrast-enhanced US with perfluorobutane to diagnose small lateral cervical lymph node metastases of papillary thyroid carcinoma. Radiology2023;307(4):e221465.
25.
KotopoulisS, PopaM, Mayoral SafontM, MurvoldE, HaugseR, LangerA, et al. SonoVue® vsSonazoidtrademark vs. Optisontrademark: Which bubble is best for low-intensity sonoporation of pancreatic ductal adenocarcinoma? Pharmaceutics2022;14(1):98.
26.
HeM, ZhuL, HuangM, ZhongL, YeZ, JiangT. Comparison between SonoVue and Sonazoid contrast-enhanced ultrasound in characterization of focal nodular hyperplasia smaller than 3 cm. J Ultras Med2021;40(10):2095–104.
27.
ImaiY, OkamotoN, TateiwaN, HasebeO, NagataA, ImaiS, et al. Assessment of treatment efficacy in radiofrequency ablation for hepatocellular carcinoma: Comparison between multiplanar reconstruction by multi-detector row CT and contrast-enhanced ultrasonography by Truagent detection mode. Hepatol Res2006;35(1):69–75.
28.
DohmenT, KataokaE, YamadaI, MiuraK, OhshimaS, ShibuyaT, et al. Efficacy of contrast-enhanced ultrasonography in radiofrequency ablation for hepatocellular carcinoma. Intern Med2012;51(1):1–7.
29.
ZhengZ, XieW, TianJ, WuJ, LuoB, XuX. Utility of sonazoid-enhanced ultrasound for the macroscopic classification of hepatocellular carcinoma: A meta-analysis. Ultrasound Med Biol2022;48(11):2165–73.
30.
MaruyamaH, SekimotoT, YokosukaO. Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience. J Gastroenterol2016;51(5):421–33.
31.
BarrRG, HuangP, LuoY, XieX, ZhengR, YanK, et al. Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid. Abdom Radiol (NY)2020;45(11):3779–88.
32.
MukundA, BansalA, PatidarY, ThaparS, SharmaMK, SarinSK. Role of contrast-enhanced ultrasound with Perfluorobutane in lesion detection, guidance for microwave ablation, and response assessment of hepatocellular carcinoma. Abdom Radiol (NY)2022;47(10):3459–67.
33.
QinS, ZhouJ, CuiR, ChenY, WangY, LiuG. Percutaneous ablation of colorectal liver metastases: a comparison between the outcomes of grayscale US guidance and Sonazoid CEUS Kupffer phase guidance using propensity score matching. Int J Hyperthermia2023;40(1):2260573.
34.
LiJX, LiXL, YuSY, XuHX. Repeated ultrasound-guided percutaneous thermal ablation combined with systemic therapy achieves a stable condition in an end-stage patient with more than 10 liver metastases from breast cancer: The importance of sonazoid assisted contrast-enhanced ultrasound and fusion imaging. Clin Hemorheol Microcirc2022;82(1):85–93.
35.
JungEM, MoranVO, EngelM, Krüger-GengeA, StroszczynskiC, JungF. Modified contrast-enhanced ultrasonography with the new high-resolution examination technique of high frame rate contrast-enhanced ultrasound (HiFR-CEUS) for characterization of liver lesions: First results. Clin Hemorheol Microcirc2023;83(1):31–46.
